Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer
First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)